Prognostic impact of prostate-specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node-positive prostate cancer

被引:5
作者
Leow, Boon Yang Jerome [1 ,5 ]
Eade, Thomas [1 ,2 ]
Hruby, George [2 ]
Lieng, Hester [1 ]
Hsiao, Edward [3 ]
Brown, Chris [2 ,4 ]
Kneebone, Andrew [1 ,2 ]
机构
[1] Gosford Hosp, Cent Coast Canc Ctr, Gosford, NSW, Australia
[2] Royal North Shore Hosp, Northern Sydney Canc Ctr, Radiat Oncol Unit, Sydney, NSW, Australia
[3] Royal North Shore Hosp, Dept Nucl Med & PET, Sydney, NSW, Australia
[4] Univ Sydney, Clin Trials Ctr, Natl Hlth & Med Res Council, Sydney, NSW, Australia
[5] Cent Coast Canc Ctr, Gosford, NSW 2250, Australia
关键词
PET imaging; prognosis; prostatic neoplasm; staging; RADIATION-THERAPY; FREE SURVIVAL; RADIOTHERAPY;
D O I
10.1111/1754-9485.13655
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: In the current American Joint Committee on Cancer staging system, patients with pelvic nodal metastases are considered stage IV prostate cancer. This study aims to investigate whether men with prostate-specific membrane antigen positron emission tomography (PSMA PET)-detected pelvic node-positive prostate cancer at diagnosis have a better outcome compared to men with node-positive disease identified on conventional imaging. Methods: This is a retrospective cohort study comparing the outcomes of men with node-positive prostate cancer and disease confined to the pelvis, staged with conventional versus PSMA PET imaging. Men had to be treated definitively with a combination of androgen deprivation therapy and radiation treatment to the prostate and pelvic lymph nodes. Kaplan-Meier and Cox regression analysis was used to compare biochemical failure-free survival (BFFS) and overall survival (OS). Results: Seventy-six men with nodal metastases confined to the pelvis were identified. Fifty-one were detected with PSMA PET while 25 were staged with conventional imaging. PSMA PET staged patients had a lower proportion of Gleason 8-10 disease (78% vs. 96%) as well as a lower median prostate-specific antigen (11 ng/mL vs. 26 ng/mL). BFFS at 4 years was 72% with PSMA PET-detected node-positive disease vs. 38% with conventionally detected node-positive disease. Four-year OS was 93% with PSMA PET staged patients vs. 76% with conventionally staged patients. On multivariate analysis, the PSMA PET staged group was associated with improved BFFS (Adjusted HR = 3.00, 95% CI 1.43, 6.29, P = 0.004) and OS (Adjusted HR = 5.81, 95% CI 1.43, 23.7, P = 0.007). Conclusion: Men with PSMA PET-detected node-positive prostate cancer confined to the pelvis have significantly better biochemical control and survival compared to those with node-positive pelvic disease identified through conventional staging.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 23 条
[11]  
Kneebone A., OPTIMAL PROSTATE STU
[12]   Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group [J].
Lieng, Hester ;
Kneebone, Andrew ;
Hayden, Amy J. ;
Christie, David R. H. ;
Davis, Brian J. ;
Eade, Thomas N. ;
Emmett, Louise ;
Holt, Tanya ;
Hruby, George ;
Pryor, David ;
Sidhom, Mark ;
Skala, Marketa ;
Yaxley, John ;
Shakespeare, Thomas P. .
RADIOTHERAPY AND ONCOLOGY, 2019, 140 :68-75
[13]   Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer [J].
Lin, Chun Chieh ;
Gray, Phillip J. ;
Jemal, Ahmedin ;
Efstathiou, Jason A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (07)
[14]   PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial [J].
Menard, Cynthia ;
Young, Sympascho ;
Zukotynski, Katherine ;
Hamilton, Robert J. ;
Benard, Francois ;
Yip, Steven ;
McCabe, Christopher ;
Saad, Fred ;
Brundage, Michael ;
Nitulescu, Roy ;
Bauman, Glenn .
BMC CANCER, 2022, 22 (01)
[15]   PEARLS-A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation [J].
Murray, Julia ;
Cruickshank, Clare ;
Bird, Thomas ;
Bell, Philip ;
Braun, John ;
Chuter, Dave ;
Ferreira, Miguel Reis ;
Griffin, Clare ;
Hassan, Shama ;
Hujairi, Nabil ;
Melcher, Alan ;
Miles, Elizabeth ;
Naismith, Olivia ;
Panades, Miguel ;
Philipps, Lara ;
Reid, Alison ;
Rekowski, Jan ;
Sankey, Pete ;
Staffurth, John ;
Syndikus, Isabel ;
Tree, Alison ;
Wilkins, Anna ;
Hall, Emma .
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 37 :130-136
[16]   The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study [J].
Roach, Paul J. ;
Francis, Roslyn ;
Emmett, Louise ;
Hsiao, Edward ;
Kneebone, Andrew ;
Hruby, George ;
Eade, Thomas ;
Nguyen, Quoc A. ;
Thompson, Benjamin D. ;
Cusick, Thomas ;
McCarthy, Michael ;
Tang, Colin ;
Ho, Bao ;
Stricker, Philip D. ;
Scott, Andrew M. .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (01) :82-88
[17]   The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Population-Based Study [J].
Rusthoven, Chad G. ;
Carlson, Julie A. ;
Waxweiler, Timothy V. ;
Raben, David ;
Dewitt, Peter E. ;
Crawford, E. David ;
Maroni, Paul D. ;
Kavanagh, Brian D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (05) :1064-1073
[18]   Pitfalls in Gallium-68 PSMA PET/CT Interpretation-A Pictorial Review [J].
Shetty, Deepa ;
Patel, Dhruv ;
Le, Ken ;
Bui, Chuong ;
Mansberg, Robert .
TOMOGRAPHY, 2018, 4 (04) :182-193
[19]   Current status of lymph node-positive prostate cancer - Incidence and predictors of outcome [J].
Swanson, Gregory P. ;
Thompson, Ian M. ;
Basler, Joseph .
CANCER, 2006, 107 (03) :439-450
[20]   Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival [J].
Tward, Jonathan D. ;
Kokeny, Kristine E. ;
Shrieve, Dennis C. .
PRACTICAL RADIATION ONCOLOGY, 2013, 3 (03) :234-240